Guardant Health Partners with Nuvalent to Advance Precision Oncology

The partnership seeks to enhance biomarker-driven drug development by improving patient selection, clinical trial efficiency, and regulatory outcomes.

California-based biotechnology company, Guardant Health, has announced a multi-year collaboration with Nuvalent to support the development and potential commercialization of targeted cancer therapies.

The collaboration will focus on leveraging Guardant’s Infinity platform, integrating both tissue and liquid biopsy solutions into Nuvalent’s oncology pipeline.

The partnership seeks to strengthen biomarker-driven drug development by enabling more précised patient selection, improving clinical trial efficiency, and regulatory outcomes.

As a part of the agreement, Guardant’s diagnostic tools will be deployed across Nuvalent’s global clinical studies, with a focus on identifying suitable patient populations for targeted therapies.

Further, both companies will evaluate opportunities to develop Guardant tissue and biopsy assays as companion diagnostics (CDx) to support potential regulatory approvals of Nuvalent’s current investigational candidates.

The companies also plan to work on joint global commercialization of therapies and associated diagnostic solutions, if approved.

The latest agreement with Nuvalent follows a January collaboration with Merck involving Guardant's Infinity Smart platform for patient enrolment in cancer studies and companion diagnostics.

Founded in 2012, Guardant Health aims to transform patient care and accelerate new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and AI analytics.

Last year, the California-based biotech company had partnered with artificial-intelligence firm Zephyr AI aimed at advancing cancer research by leveraging real-world clinical and biological data in combination with machine-learning algorithms.

Stay tuned for more such updates on Digital Health News